NeuroSense Therapeutics Ltd. (NRSN)

1.7100 +0.0500 (+3.01%) As of 01:05PM EDT. Market open.

NeuroSense Therapeutics Ltd.

Building B
11 HaMenofim Street
Herzliya 4672562
Israel
972 9 799 6183
https://www.neurosense-tx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Alon Ben-Noon	Co-Founder, CEO & Director	N/A	N/A	1979
Mr. Or Eisenberg	Chief Financial Officer	N/A	N/A	1981
Ms. Hagit Binder	VP of Operations	N/A	N/A	1978
Ms. Yael Barak	Head of QA & Compliance	N/A	N/A	1970
Ms. Nedira Salzman-Frenkel	Global Head of Bus. Devel.	N/A	N/A	1988
Dr. Shiran Zimri Ph.D.	Head of Scientific Program	N/A	N/A	1985
Dr. Ferenc Tracik M.D.	Chief Medical Officer	N/A	N/A	1965
Dr. Niva Russek-Blum Ph.D.	Global Head of Discovery & IP Generator	N/A	N/A	1975
Dr. Sharon Cohen Vered Ph.D.	Global Head of CMC	N/A	N/A	1966

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Corporate governance

NeuroSense Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.